- Home
- / PharmaCyte Biotech
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
PharmaCyte Biotech financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.9
2024-10-29
Market Capitalization
$14.7 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 66.6K | 12.2K | ||||||||||||
| Cost of goods sold | 19.4K | 9.6K | ||||||||||||
| Gross profit | 47.2K | 2.5K | ||||||||||||
| Gross profit margin, % | 70.9% | 20.9% | ||||||||||||
| General and administrative expense | 416.2K | 617.3K | 2.2M | 2.2M | 2.3M | 744.8K | 1.8M | 1.4M | 1.2M | 418.1K | 1.1M | 1.1M | 2.1M | 3.9M |
| Operating expense total | 2.0M | 1.7M | 19.0M | 13.3M | 6.1M | 1.9M | 3.8M | 1.8M | 1.5M | 1.3M | 1.8M | 1.6M | 2.5M | 4.4M |
| EBIT | (1.9M) | (1.7M) | (19.0M) | (13.3M) | (6.1M) | (4.4M) | (7.0M) | (4.1M) | (3.8M) | (3.6M) | (4.4M) | (6.5M) | (8.5M) | (4.4M) |
| EBIT margin, % | -2928.5% | -13851.7% | ||||||||||||
| Interest income | 2.6K | 1.1K | 157.6K | 1.9M | 3.4M | 1.4M | ||||||||
| Interest expense | 241.2K | 112.7K | 3.0K | |||||||||||
| Net Income | (1.9M) | (1.6M) | (27.3M) | (9.9M) | (6.1M) | (4.4M) | (6.8M) | (4.1M) | (3.8M) | (3.6M) | (4.2M) | (4.3M) | 333.8K | 30.7M |
| EPS | (0.2) | (1.8) | 3.2 |